Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Buy" by Analysts

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) has been given a consensus rating of "Buy" by the ten analysts that are covering the stock, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $136.50.

A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Guggenheim reiterated a "buy" rating and issued a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, March 12th. Bank of America dropped their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Finally, The Goldman Sachs Group dropped their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st.

Vaxcyte Stock Up 6.3%

Shares of NASDAQ:PCVX traded up $2.19 during trading on Thursday, hitting $36.99. The stock had a trading volume of 1,582,492 shares, compared to its average volume of 1,430,973. Vaxcyte has a 12 month low of $27.66 and a 12 month high of $121.06. The company has a market capitalization of $4.77 billion, a PE ratio of -8.04 and a beta of 1.20. The firm's fifty day moving average is $32.26 and its 200 day moving average is $64.78.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the previous year, the company earned ($0.85) earnings per share. Equities research analysts expect that Vaxcyte will post -4.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PCVX. RA Capital Management L.P. increased its holdings in Vaxcyte by 40.3% in the 1st quarter. RA Capital Management L.P. now owns 12,189,149 shares of the company's stock worth $460,262,000 after acquiring an additional 3,499,959 shares in the last quarter. Wellington Management Group LLP increased its holdings in Vaxcyte by 44.4% in the 1st quarter. Wellington Management Group LLP now owns 6,416,930 shares of the company's stock worth $242,303,000 after acquiring an additional 1,972,918 shares in the last quarter. Capital Research Global Investors increased its holdings in Vaxcyte by 26.8% in the 4th quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock worth $508,393,000 after acquiring an additional 1,312,302 shares in the last quarter. Norges Bank purchased a new stake in Vaxcyte in the 4th quarter worth approximately $90,069,000. Finally, Baker BROS. Advisors LP increased its holdings in Vaxcyte by 1,211.0% in the 1st quarter. Baker BROS. Advisors LP now owns 640,885 shares of the company's stock worth $24,200,000 after acquiring an additional 592,000 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.